Drug intelligence / Profile preview

Lidoflazine

Development stage: Unknown
Lead developer: Janssen Pharmaceutica
Modality: Small Molecules
Administration: Oral

Overview

Lidoflazine is a piperazine calcium channel blocker used primarily as a coronary vasodilator with some antiarrhythmic action. It was discovered by Janssen Pharmaceutica in 1964 and is indicated for cardiovascular diseases, particularly for the treatment of angina pectoris. Lidoflazine also acts as a high-affinity blocker of the HERG potassium channel.

Brand names: AngexClinium
Other names: CorflazineLidoflazinLidoflazinumOrdiflazine

Targets

CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)KCNH2 (Voltage-gated potassium channel subfamily H member 2)

Beyond the preview

Go deeper on Lidoflazine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Lidoflazine.

Explore the full profile